Report Overview

The EU Asthma Treatment market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

Asthma is a chronic inflammatory disease of the airways that causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. In the EU, almost 10million people <45years of age have asthma. The prevalence of asthma in the European Union (EU) is 8.2% in adults and 9.4% in children. According to World Health Organization (WHO), it is estimated that every year 25billion disability-adjusted life years (DALYs) are lost because of asthma, of this, 5.2billion DALYs are lost within the EU. Asthma is the most common non-communicable disease among children. In the majority of cases, asthma is mild, but severe asthma occurs in 1020% of patients



Market Growth Drivers

Increasing incidence of asthma cases, advanced inhaler devices, innovation in biological drugs, increasing pollution level, growing aging population are expected to drive the EU market for asthma treatment. Asthma is considered to be the most common chronic disease worldwide. The growing need for advanced therapeutics will subsequently promote the growth of the market. The launch of low cost-effective therapeutics such as generic equivalents can be an essential factor in augmenting the growth of the market during the forecast period. The high costs associated with asthma inhalers, which are often considered the primary treatment for Asthma will limit the adoption of asthma therapeutics